A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants with Proteinuric Chronic Kidney Disease

Study identifier:D7551C00001

ClinicalTrials.gov identifier:NCT04492722

EudraCT identifier:2020-002263-54

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease

Medical condition

Chronic Kidney Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD5718, AZD5718, AZD5718, Dapagliflozin 10 mg, Dapagliflozin 10 mg, Dapagliflozin 10 mg, Dapagliflozin 10 mg, Placebo

Sex

All

Actual enrollment

613

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 01 Oct 2020
Primary Completion Date: 06 Sept 2022
Study Completion Date: 06 Sept 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Parexel International, George Clinical Pty Ltd.

Inclusion and exclusion criteria